Sinopharm Group Co Top Insiders
Sinopharm Group employs about 113.2 K people. The company is managed by 8 executives with a total tenure of roughly 64 years, averaging almost 8.0 years of service per executive, having 14154.25 employees per reported executive. Examination of Sinopharm Group's management performance can provide insight into the company performance.
| Shuangjun Xu President Vice President |
| Maisong Cai President Vice President |
Sinopharm |
Sinopharm Group Management Team Effectiveness
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.Sinopharm Group Workforce Comparison
Sinopharm Group Co is currently regarded as top stock in number of employees category among its peers. The total workforce of Medical Distribution industry is at this time estimated at about 358,814. Sinopharm Group totals roughly 113,234 in number of employees claiming about 32% of all equities under Medical Distribution industry.
The company has Profit Margin (PM) of 0.01 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04. Sinopharm Group Notable Stakeholders
A Sinopharm Group stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sinopharm Group often face trade-offs trying to please all of them. Sinopharm Group's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sinopharm Group's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shuangjun Xu | Vice President | Profile | |
| Maisong Cai | Vice President | Profile | |
| Xiuchang Jiang | CFO VP | Profile | |
| Yijian Wu | Non-Executive Director | Profile | |
| Qingming Yu | Executive Director | Profile | |
| Yong Liu | Chief Legal Advisor and VP | Profile | |
| Xiaojuan Li | Chief Officer | Profile | |
| Wanyong Lian | Supervisor | Profile |
Sinopharm Group Workforce Analysis
Traditionally, organizations such as Sinopharm Group use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sinopharm Group within its industry.Sinopharm Group Manpower Efficiency
Return on Sinopharm Group Manpower
| Revenue Per Employee | 4.6M | |
| Revenue Per Executive | 65.1B | |
| Net Income Per Employee | 68.5K | |
| Net Income Per Executive | 969.8M | |
| Working Capital Per Employee | 284.9K | |
| Working Capital Per Executive | 4B |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |